Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2. / Scotti, Andrea; Pagnesi, Matteo; Kim, Won Keun; Schäfer, Ulrich; Barbanti, Marco; Costa, Giuliano; Baggio, Sara; Casenghi, Matteo; De Marco, Federico; Vanhaverbeke, Maarten; Sondergaard, Lars; Wolf, Alexander; Schofer, Joachim; Ancona, Marco Bruno; Montorfano, Matteo; Kornowski, Ran; Assa, Hana Vaknin; Toggweiler, Stefan; Ielasi, Alfonso; Hildick-Smith, David; Windecker, Stephan; Schmidt, Albrecht; Buono, Andrea; Maffeo, Diego; Siqueira, Dimytri; Giannini, Francesco; Adamo, Marianna; Massussi, Mauro; Wood, David A.; Sinning, Jan Malte; Van der Heyden, Jan; van Ginkel, Dirk Jan; Van Mieghem, Nicholas; Veulemans, Verena; Mylotte, Darren; Tzalamouras, Vasileios; Taramasso, Maurizio; Estévez-Loureiro, Rodrigo; Colombo, Antonio; Mangieri, Antonio; Latib, Azeem; NEOPRO & NEOPRO-2 investigators.

I: EuroIntervention, Bind 18, Nr. 10, 2022, s. 804-811.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Scotti, A, Pagnesi, M, Kim, WK, Schäfer, U, Barbanti, M, Costa, G, Baggio, S, Casenghi, M, De Marco, F, Vanhaverbeke, M, Sondergaard, L, Wolf, A, Schofer, J, Ancona, MB, Montorfano, M, Kornowski, R, Assa, HV, Toggweiler, S, Ielasi, A, Hildick-Smith, D, Windecker, S, Schmidt, A, Buono, A, Maffeo, D, Siqueira, D, Giannini, F, Adamo, M, Massussi, M, Wood, DA, Sinning, JM, Van der Heyden, J, van Ginkel, DJ, Van Mieghem, N, Veulemans, V, Mylotte, D, Tzalamouras, V, Taramasso, M, Estévez-Loureiro, R, Colombo, A, Mangieri, A, Latib, A & NEOPRO & NEOPRO-2 investigators 2022, 'Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2', EuroIntervention, bind 18, nr. 10, s. 804-811. https://doi.org/10.4244/EIJ-D-22-00289

APA

Scotti, A., Pagnesi, M., Kim, W. K., Schäfer, U., Barbanti, M., Costa, G., Baggio, S., Casenghi, M., De Marco, F., Vanhaverbeke, M., Sondergaard, L., Wolf, A., Schofer, J., Ancona, M. B., Montorfano, M., Kornowski, R., Assa, H. V., Toggweiler, S., Ielasi, A., ... NEOPRO & NEOPRO-2 investigators (2022). Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2. EuroIntervention, 18(10), 804-811. https://doi.org/10.4244/EIJ-D-22-00289

Vancouver

Scotti A, Pagnesi M, Kim WK, Schäfer U, Barbanti M, Costa G o.a. Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2. EuroIntervention. 2022;18(10):804-811. https://doi.org/10.4244/EIJ-D-22-00289

Author

Scotti, Andrea ; Pagnesi, Matteo ; Kim, Won Keun ; Schäfer, Ulrich ; Barbanti, Marco ; Costa, Giuliano ; Baggio, Sara ; Casenghi, Matteo ; De Marco, Federico ; Vanhaverbeke, Maarten ; Sondergaard, Lars ; Wolf, Alexander ; Schofer, Joachim ; Ancona, Marco Bruno ; Montorfano, Matteo ; Kornowski, Ran ; Assa, Hana Vaknin ; Toggweiler, Stefan ; Ielasi, Alfonso ; Hildick-Smith, David ; Windecker, Stephan ; Schmidt, Albrecht ; Buono, Andrea ; Maffeo, Diego ; Siqueira, Dimytri ; Giannini, Francesco ; Adamo, Marianna ; Massussi, Mauro ; Wood, David A. ; Sinning, Jan Malte ; Van der Heyden, Jan ; van Ginkel, Dirk Jan ; Van Mieghem, Nicholas ; Veulemans, Verena ; Mylotte, Darren ; Tzalamouras, Vasileios ; Taramasso, Maurizio ; Estévez-Loureiro, Rodrigo ; Colombo, Antonio ; Mangieri, Antonio ; Latib, Azeem ; NEOPRO & NEOPRO-2 investigators. / Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2. I: EuroIntervention. 2022 ; Bind 18, Nr. 10. s. 804-811.

Bibtex

@article{d286a2134f7b4270bc594036ea80904f,

title = "Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2",

abstract = "Background: Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated with a non-negligible incidence of paravalvular aortic regurgitation (AR). The new-generation ACURATE neo2 has been designed to mitigate this limitation. Aims: The aim of the study was to compare TAVR with the ACURATE neo and neo2 devices. Methods: The NEOPRO and NEOPRO-2 registries retrospectively included patients undergoing transfemoral TAVR with self-expanding valves at 24 and 20 centres, respectively. Patients receiving the ACURATE neo and neo2 devices (from January 2012 to December 2021) were included in this study. Predischarge and 30-day VARC–3 defined outcomes were evaluated. The primary endpoint was predischarge moderate or severe paravalvular AR. Subgroup analyses per degree of aortic valve calcification were performed. Results: A total of 2,026 patients (neo: 1,263, neo2: 763) were included. Predischarge moderate or severe paravalvular AR was less frequent for the neo2 group (2% vs 5%; p<0.001), resulting in higher VARC-3 intended valve performance (96% vs 90%; p<0.001). Furthermore, more patients receiving the neo2 had none/trace paravalvular AR (59% vs 38%; p<0.001). The reduction in paravalvular AR with neo2 was mainly observed with heavy aortic valve calcification. New pacemaker implantation and VARC-3 technical and device success rates were similar between the 2 groups; there were more frequent vascular and bleeding complications for the neo device. Similar 1-year survival was detected after TAVR (neo2: 90% vs neo: 87%; p=0.14). Conclusions: TAVR with the ACURATE neo2 device was associated with a lower prevalence of moderate or severe paravalvular AR and more patients with none/trace paravalvular AR. This difference was particularly evident with heavy aortic valve calcification.",

keywords = "aortic stenosis, atrio-ventricular block, conduction abnormalities, TAVR",

author = "Andrea Scotti and Matteo Pagnesi and Kim, {Won Keun} and Ulrich Sch{\"a}fer and Marco Barbanti and Giuliano Costa and Sara Baggio and Matteo Casenghi and {De Marco}, Federico and Maarten Vanhaverbeke and Lars Sondergaard and Alexander Wolf and Joachim Schofer and Ancona, {Marco Bruno} and Matteo Montorfano and Ran Kornowski and Assa, {Hana Vaknin} and Stefan Toggweiler and Alfonso Ielasi and David Hildick-Smith and Stephan Windecker and Albrecht Schmidt and Andrea Buono and Diego Maffeo and Dimytri Siqueira and Francesco Giannini and Marianna Adamo and Mauro Massussi and Wood, {David A.} and Sinning, {Jan Malte} and {Van der Heyden}, Jan and {van Ginkel}, {Dirk Jan} and {Van Mieghem}, Nicholas and Verena Veulemans and Darren Mylotte and Vasileios Tzalamouras and Maurizio Taramasso and Rodrigo Est{\'e}vez-Loureiro and Antonio Colombo and Antonio Mangieri and Azeem Latib and {NEOPRO & NEOPRO-2 investigators}",

year = "2022",

doi = "10.4244/EIJ-D-22-00289",

language = "English",

volume = "18",

pages = "804--811",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Digital & Publishing",

number = "10",

}

RIS

TY - JOUR

T1 - Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self-expanding ACURATE neo2

AU - Scotti, Andrea

AU - Pagnesi, Matteo

AU - Kim, Won Keun

AU - Schäfer, Ulrich

AU - Barbanti, Marco

AU - Costa, Giuliano

AU - Baggio, Sara

AU - Casenghi, Matteo

AU - De Marco, Federico

AU - Vanhaverbeke, Maarten

AU - Sondergaard, Lars

AU - Wolf, Alexander

AU - Schofer, Joachim

AU - Ancona, Marco Bruno

AU - Montorfano, Matteo

AU - Kornowski, Ran

AU - Assa, Hana Vaknin

AU - Toggweiler, Stefan

AU - Ielasi, Alfonso

AU - Hildick-Smith, David

AU - Windecker, Stephan

AU - Schmidt, Albrecht

AU - Buono, Andrea

AU - Maffeo, Diego

AU - Siqueira, Dimytri

AU - Giannini, Francesco

AU - Adamo, Marianna

AU - Massussi, Mauro

AU - Wood, David A.

AU - Sinning, Jan Malte

AU - Van der Heyden, Jan

AU - van Ginkel, Dirk Jan

AU - Van Mieghem, Nicholas

AU - Veulemans, Verena

AU - Mylotte, Darren

AU - Tzalamouras, Vasileios

AU - Taramasso, Maurizio

AU - Estévez-Loureiro, Rodrigo

AU - Colombo, Antonio

AU - Mangieri, Antonio

AU - Latib, Azeem

AU - NEOPRO & NEOPRO-2 investigators

PY - 2022

Y1 - 2022

N2 - Background: Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated with a non-negligible incidence of paravalvular aortic regurgitation (AR). The new-generation ACURATE neo2 has been designed to mitigate this limitation. Aims: The aim of the study was to compare TAVR with the ACURATE neo and neo2 devices. Methods: The NEOPRO and NEOPRO-2 registries retrospectively included patients undergoing transfemoral TAVR with self-expanding valves at 24 and 20 centres, respectively. Patients receiving the ACURATE neo and neo2 devices (from January 2012 to December 2021) were included in this study. Predischarge and 30-day VARC–3 defined outcomes were evaluated. The primary endpoint was predischarge moderate or severe paravalvular AR. Subgroup analyses per degree of aortic valve calcification were performed. Results: A total of 2,026 patients (neo: 1,263, neo2: 763) were included. Predischarge moderate or severe paravalvular AR was less frequent for the neo2 group (2% vs 5%; p<0.001), resulting in higher VARC-3 intended valve performance (96% vs 90%; p<0.001). Furthermore, more patients receiving the neo2 had none/trace paravalvular AR (59% vs 38%; p<0.001). The reduction in paravalvular AR with neo2 was mainly observed with heavy aortic valve calcification. New pacemaker implantation and VARC-3 technical and device success rates were similar between the 2 groups; there were more frequent vascular and bleeding complications for the neo device. Similar 1-year survival was detected after TAVR (neo2: 90% vs neo: 87%; p=0.14). Conclusions: TAVR with the ACURATE neo2 device was associated with a lower prevalence of moderate or severe paravalvular AR and more patients with none/trace paravalvular AR. This difference was particularly evident with heavy aortic valve calcification.

AB - Background: Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated with a non-negligible incidence of paravalvular aortic regurgitation (AR). The new-generation ACURATE neo2 has been designed to mitigate this limitation. Aims: The aim of the study was to compare TAVR with the ACURATE neo and neo2 devices. Methods: The NEOPRO and NEOPRO-2 registries retrospectively included patients undergoing transfemoral TAVR with self-expanding valves at 24 and 20 centres, respectively. Patients receiving the ACURATE neo and neo2 devices (from January 2012 to December 2021) were included in this study. Predischarge and 30-day VARC–3 defined outcomes were evaluated. The primary endpoint was predischarge moderate or severe paravalvular AR. Subgroup analyses per degree of aortic valve calcification were performed. Results: A total of 2,026 patients (neo: 1,263, neo2: 763) were included. Predischarge moderate or severe paravalvular AR was less frequent for the neo2 group (2% vs 5%; p<0.001), resulting in higher VARC-3 intended valve performance (96% vs 90%; p<0.001). Furthermore, more patients receiving the neo2 had none/trace paravalvular AR (59% vs 38%; p<0.001). The reduction in paravalvular AR with neo2 was mainly observed with heavy aortic valve calcification. New pacemaker implantation and VARC-3 technical and device success rates were similar between the 2 groups; there were more frequent vascular and bleeding complications for the neo device. Similar 1-year survival was detected after TAVR (neo2: 90% vs neo: 87%; p=0.14). Conclusions: TAVR with the ACURATE neo2 device was associated with a lower prevalence of moderate or severe paravalvular AR and more patients with none/trace paravalvular AR. This difference was particularly evident with heavy aortic valve calcification.

KW - aortic stenosis

KW - atrio-ventricular block

KW - conduction abnormalities

KW - TAVR

U2 - 10.4244/EIJ-D-22-00289

DO - 10.4244/EIJ-D-22-00289

M3 - Journal article

C2 - 35678222

AN - SCOPUS:85142403593

VL - 18

SP - 804

EP - 811

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 10

ER -

ID: 334875571